Aurora Kinase Inhibitor 3

Modify Date: 2024-01-14 09:17:30

Aurora Kinase Inhibitor 3 structure	Common Name	Aurora Kinase Inhibitor 3
	CAS Number	879127-16-9	Molecular Weight	413.39600
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₂₁H₁₈F₃N₅O	Melting Point	N/A
	MSDS	Chinese USA	Flash Point	N/A

Use of Aurora Kinase Inhibitor 3

Aurora Kinase Inhibitor 3 is a strong and selective Aurora A kinase inhibitor with an IC50 of 42 nM, and weakly inhibits EGFR with an IC50>10 μM. Aurora Kinase Inhibitor 3 has a binding mode with the cyclopropanecarboxylic acid moiety directed towards the solvent exposed region of the ATP-binding pocket, and several induced structural changes in the active-site compared with other published AIK structures[1].

Name	N-[3-[[4-[3-(trifluoromethyl)anilino]pyrimidin-2-yl]amino]phenyl]cyclopropanecarboxamide
Synonym	More Synonyms

Description	Aurora Kinase Inhibitor 3 is a strong and selective Aurora A kinase inhibitor with an IC50 of 42 nM, and weakly inhibits EGFR with an IC50>10 μM. Aurora Kinase Inhibitor 3 has a binding mode with the cyclopropanecarboxylic acid moiety directed towards the solvent exposed region of the ATP-binding pocket, and several induced structural changes in the active-site compared with other published AIK structures[1].
Related Catalog	Signaling Pathways >> Epigenetics >> Aurora Kinase Signaling Pathways >> Cell Cycle/DNA Damage >> Aurora Kinase Research Areas >> Others
Target	Aurora A:42 nM (IC50)
References	[1]. Tari LW, et al. Structural basis for the inhibition of Aurora A kinase by a novel class of high affinitydisubstituted pyrimidine inhibitors. Bioorg Med Chem Lett. 2007 Feb 1;17(3):688-91.

Molecular Formula	C₂₁H₁₈F₃N₅O
Molecular Weight	413.39600
Exact Mass	413.14600
PSA	85.66000
LogP	5.47550

RIDADR	NONH for all modes of transport
HS Code	2933599090

HS Code	2933599090
Summary	2933599090. other compounds containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

Synthetic lethal screen of an EGFR-centered network to improve targeted therapies.

Sci. Signal. 3 , ra67, (2010)

Intrinsic and acquired cellular resistance factors limit the efficacy of most targeted cancer therapeutics. Synthetic lethal screens in lower eukaryotes suggest that networks of genes closely linked t...

Enhanced genetic instability and dasatinib sensitivity in mammary tumor cells lacking NEDD9.

Cancer Res. 70 , 8907-16, (2010)

Elevated expression of the NEDD9/HEF1/Cas-L scaffolding protein promotes tumor cell invasion and metastasis in multiple cancer cell types. Conversely, generation of mammary tumors in the mouse mammary...

Discovery of EGFR selective 4,6-disubstituted pyrimidines from a combinatorial kinase-directed heterocycle library.

J. Am. Chem. Soc. 128 , 2182-2183, (2006)

The epidermal growth factor receptor (EGFR) tyrosine kinase was one of the first receptor tyrosine kinases to be targeted for drug development by the pharmaceutical industry due to its ubiquitous over...

Cyclopropanecarboxylic acid-(3-(4-(3-trifluoromethyl-phenylamino)-pyrimidin-2-ylamino)-phenyl)-amide

Anilinopyrimidine1

2np8

Aurora Kinase Inhibitor III

N-{3-[(4-{[3-(trifluoromethyl)phenyl]amino}pyrimidin-2-yl)amino]phenyl}cyclopropanecarboxamide